The Repetitive Transcranial Magnetic Stimulation (rTMS) for Amphetamine-type Stimulants Addiction
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- Change from Baseline Craving for ATS assessed by Visual Analog Scales (VAS) at 1 month
研究概览
简要总结
The repetitive transcranial magnetic stimulation (rTMS) will be used to treat amphetamine-type stimulant (ATS) addiction.
详细描述
The Glutamate and GABA deficits in prefrontal cortex play a vital role in ATS addiction and relapse, and proposed repetitive transcranial magnetic stimulation (rTMS) as a novel interventions. Focused on evaluating Glutamate/GABA functions in prefrontal cortex and functional connectivity with deep brain regions, neuropsychological tests, biochemical tests, magnetic resonance spectroscopy (MRS) and functional MRI will be used to investigate the neurobiological mechanism of ATS addiction and relapse. These methods will also be used to evaluate the efficacy of the novel intervention and investigate the mechanisms. The study will be very helpful to develop novel interventions in clinical practice and decrease ATS-related harm for both the patients and their families.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •In accordance with the Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5) for methamphetamine (MA) use disorders
- •Dextromanual
排除标准
- •Have a disease that affect cognitive function such as history of head injury, cerebrovascular disease, epilepsy, etc
- •Have cognitive-promoting drugs in the last 6 months
- •Other substance abuse or dependence in recent five years (except nicotine)
- •Mental impairment, Intelligence Quotient (IQ) < 70
- •Mental disorders
- •Physical disease
结局指标
主要结局
Change from Baseline Craving for ATS assessed by Visual Analog Scales (VAS) at 1 month
时间窗: Baseline and 1 month
evaluate all participants' craving for ATS by Visual Analog Scales (VAS)
次要结局
- Number of participants who relapse(1 month)
- Depression status assessed by Patient Health Questionnaire-9(PHQ-9)(1 month)
- Anxiety status assessed by Generalized Anxiety Disorder Screener (GAD-7)(1 month)
- Cognitive function assessed by Cogstate Battery(1 month)
- Functional connectivity assessed by MRI(1 month)